 Pancreatic cancer is the 5th leading cause of cancer mortality in the United States, with a 5 year mortality rate of over 95. With limited treatments available for cure or prolongation of survival, quality of life issues, such as the optimal treatment and understanding of depression, become an important focus of care in this population. Clinical Depression Major Depressive Syndrome occurs in up to 50 of patients with pancreatic cancer, and is significantly more common than in other cancers. Accumulating evidence suggests a potential role for endogenous cytokines, specifically interleukin-1 IL-1, interleukin-6 IL-6 and tumor necrosis factor alpha TNF-alpha in the development of depression in the medically ill, including cancer patients. These same cytokines have been noted to be elevated in pancreas cancer patients. The main goal of this pilot study is to examine the role of specific endogenous cytokines IL-1, IL-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma in the development of Major Depressive Syndrome MDS in patients with pancreatic cancer. To achieve our goal, we will examine the relationships between serum cytokines IL-1, IL-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma and clinical depression i.e. MDS utilizing a cross sectional design in 4 samples of patients: a Pancreas cancer patients with a DSM-IV diagnosis of MDS N25; b Pancreas cancer patients without a DSM-IV diagnosis of MDS N25; c Healthy Controls with a DSM-IV diagnosis of MDS N25; and d Healthy Controls without a DSM-IV diagnosis of MDS N25. Measures will include a structural clinical interview for DSM-IV diagnosis SCID of Major Depressive Syndrome, as well as measures of depressive symptom severity, fatigue severity, concentration and attention, and cognitive function. Plasma concentrations of endogenous cytokines IL-1, IL-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma will be measured utilizing standard assays. Our specific aims are: 1 To preliminarily examine the relationships between plasma concentrations of endogenous cytokines IL-1, Il-6, TNF-alpha, as well as IL-10, Il-15 and IFNgamma and a DSM-IV diagnosis of Major Depressive Syndrome in patients with pancreas cancer and healthy controls; 2 To explore the relationships between plasma concentrations of endogenous cytokines Il-1, Il-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma and the phenomenology and severity of depressive symptoms, presence and severity of fatigue, and degree of impairment in attention, concentration and cognition, in depressed patients with pancreas cancer and healthy depressed controls. The results of this pilot study will be utilized to seek NIH funding for larger, longitudinal, multi-institutional, studies examining the role of endogenous cytokines in pancreas cancer patients, as well as clinical intervention trials for the treatment of clinical depression in pancreas cancer patients that utilize specific cytokine antagonists as adjuncts to antidepressant drug therapies. 